Novartis AG (NVS)
98.58
+0.23
(+0.23%)
USD |
NYSE |
Apr 25, 09:50
Novartis Free Cash Flow (Quarterly): 1.764B for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.764B |
September 30, 2023 | 4.874B |
June 30, 2023 | 2.58B |
March 31, 2023 | 2.487B |
December 31, 2022 | 3.613B |
September 30, 2022 | 4.422B |
June 30, 2022 | 3.172B |
March 31, 2022 | 790.00M |
December 31, 2021 | 3.322B |
September 30, 2021 | 4.386B |
June 30, 2021 | 3.535B |
March 31, 2021 | 1.272B |
December 31, 2020 | 2.982B |
September 30, 2020 | 2.529B |
June 30, 2020 | 3.509B |
March 31, 2020 | 2.045B |
December 31, 2019 | 2.904B |
September 30, 2019 | 4.00B |
June 30, 2019 | 2.507B |
March 31, 2019 | 1.957B |
December 31, 2018 | 3.116B |
September 30, 2018 | 3.209B |
June 30, 2018 | 3.459B |
March 31, 2018 | 1.84B |
December 31, 2017 | 2.89B |
Date | Value |
---|---|
September 30, 2017 | 2.917B |
June 30, 2017 | 3.029B |
March 31, 2017 | 1.491B |
December 31, 2016 | 2.81B |
September 30, 2016 | 2.517B |
June 30, 2016 | 2.436B |
March 31, 2016 | 833.00M |
December 31, 2015 | 3.189B |
September 30, 2015 | 2.346B |
June 30, 2015 | 1.868B |
March 31, 2015 | 989.00M |
December 31, 2014 | 4.37B |
September 30, 2014 | 3.012B |
June 30, 2014 | 2.378B |
March 31, 2014 | 733.00M |
December 31, 2013 | 3.374B |
September 30, 2013 | 3.50B |
June 30, 2013 | 1.744B |
March 31, 2013 | 1.178B |
December 31, 2012 | 3.948B |
September 30, 2012 | 3.311B |
June 30, 2012 | 2.271B |
March 31, 2012 | 1.892B |
December 31, 2011 | 4.049B |
September 30, 2011 | 3.65B |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
790.00M
Minimum
Mar 2022
4.874B
Maximum
Sep 2023
2.984B
Average
2.982B
Median
Dec 2020
Free Cash Flow (Quarterly) Benchmarks
Sandoz Group AG | -- |
Roche Holding AG | -- |
Amgen Inc | 289.00M |
Incyte Corp | 145.46M |
MorphoSys AG | -- |